Major Heart Studies Highlight New Approaches to Stroke Prevention and Heart Rhythm Treatment

Several cardiovascular research studies presented at the American Heart Association conference may influence how doctors manage patients with complex heart and blood-vessel conditions.

The American College of Cardiology's 13 November research recap highlighted seven studies covering different areas of cardiovascular medicine.

One major topic was the OPTIMAL-STROKE trial, which examined whether intensive blood-pressure control targeting a systolic pressure of 120 mm Hg or less could reduce major cardiovascular events in people with elevated blood pressure and a previous ischaemic stroke or transient ischaemic attack.

Other studies examined ziltivekimab, an anti-inflammatory treatment being investigated in people with atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation, and pelacarsen, a treatment targeting lipoprotein(a), an inherited cardiovascular risk factor.

The recap also discussed updated evidence on statin therapy, yoga-based cardiac rehabilitation in people with diabetes, left bundle-branch pacing and treatment approaches following atrial-fibrillation ablation.

These studies address different patient groups and should not be interpreted as one new treatment recommendation. Their results require careful consideration of trial design, safety and clinical applicability before changing individual treatment plans.